PatternsRadar
Sign in

NGLFINENGL Fine-Chem Limited

NSE
Full chart
3,122.10INR+133.80 (+4.48%)Close · 6 Oct 2026
12 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹1,929 CrMarket cap
33.7P/E (TTM)
28.7%Delivery

Filings & corporate actions

17 results filed
CSV
Next results · Q2 FY27
Expected 29 Oct 2026 – 12 Nov 2026
Estimate: filed 29–43 days after quarter end, last 4 times
Dividend
₹1.75 per share · last 18 Aug 2026
2026
  • 18 AugdividendDividend · ₹1.75 per share+4.0%
  • 12 AugresultsResults · Q1 FY27 · consolidated and standalone+0.8%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026+7.6%NSE
  • 22 MayresultsResults · Q4 FY26 · consolidated and standalone+9.3%NSE
  • 20 AprshareholdingShareholding · 31 Mar 2026+3.3%NSE
  • 3 FebresultsResults · Q3 FY26 · consolidated and standalone+20.0%NSE
  • 14 JanshareholdingShareholding · 31 Dec 2025+2.3%NSE

Reaction to results · all yearsrose on day 0 in 7 of 17 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2712 Aug 2026+0.8%-11.0%-20.0%2.1×
Q4 FY2622 May 2026+9.3%+9.5%+25.9%7.5×
Q3 FY263 Feb 2026+20.0%+23.9%+29.6%6.5×
Q2 FY2612 Nov 2025-1.2%-3.6%-8.6%0.7×
Q1 FY261 Aug 2025-2.5%-7.1%+12.6%1.5×
Q4 FY2522 May 2025-2.0%-11.4%-22.2%0.1×
Q3 FY258 Feb 2025-20.0%-44.3%-37.3%18.8×
Q2 FY259 Nov 2024-2.7%-12.5%-7.9%3.1×
Q1 FY2513 Aug 2024-2.3%-3.4%-12.1%0.4×
Q4 FY2422 May 2024-2.1%-1.8%+1.6%0.5×
Q3 FY2413 Feb 2024-2.3%+16.2%+14.9%3.1×
Q2 FY2411 Nov 2023+6.5%+4.0%+8.2%4.2×
Q1 FY244 Aug 2023+9.3%-0.3%+3.9%7.3×
Q4 FY2316 May 2023-0.6%-8.2%+6.1%0.6×
Q3 FY2310 Feb 2023+3.4%-3.0%-16.8%2.5×
Q2 FY2329 Oct 2022+11.3%+6.7%+22.7%12.2×
Q1 FY2311 Aug 2022-4.8%-6.5%-10.1%7.6×
Average+1.2%-3.1%-0.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+33.6%
Profit YoY+99.1%
Interest cost YoY+35.9%
Revenue QoQ-6.7%
Profit QoQ+36.4%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+22.3%+23.5%————
Profit+16.6%+25.4%————

Key data

CSV
Open3,032.90
Day range2,995.00 – 3,184.00
52-week range1,271.00 – 3,602.00
From 52w high-13.3%
RSI (14)62.2
ATR (14)160.59
Volume18.1K
Avg volume (20D)9.9K
Rel volume1.83×
Volatility (1Y)57.4%
Turnover₹5.6Cr
SMA 50 / 2002,992.70 / 2,470.61

Delivery percentage

Latest · 6 Oct 202628.7%
20-day avg47.3%
1-year avg56.9%
Percentile (own history)2nd
Range13.3–100.0%
Sessions1,050

Over the last 20 sessions NGLFINE settled 47.3% of its traded quantity, which is above average for an NSE equity. Its one-year average is 56.9%, so recent sessions are running 9.6 points lower than usual. The latest session ranks higher than 2% of the 1,050 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+4.48%+14.36%+6.16%+0.96%+46.40%+124.85%

Valuation

CSV
Market cap₹1,929 Cr
P/E (TTM)33.7
EPS (TTM)92.58
Shares outstanding61.78L
Listed8 Jul 2022

Ownership

CSV
Promoter72.49%
Promoter Δ QoQ-0.25 pp
Public27.51%
FII0.05%
DII0.02%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)120.3127.5149.2139.2
YoY chg+28.6%+43.1%+57.1%+33.6%
Net profit (₹ Cr)9.615.713.518.4
YoY chg-1.9%+1129.1%+2380.3%+99.1%
Net margin8.0%12.3%9.0%13.2%
EPS15.5825.4021.8329.78

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 72.49% · public 27.51%
27 May 2022: promoter 73.81%30 Jun 2022: promoter 73.81%30 Sept 2022: promoter 73.81%31 Dec 2022: promoter 73.81%31 Mar 2023: promoter 73.53%30 Jun 2023: promoter 73.53%30 Sept 2023: promoter 73.06%31 Dec 2023: promoter 73.06%31 Mar 2024: promoter 72.74%30 Jun 2024: promoter 72.74%30 Sept 2024: promoter 72.74%31 Dec 2024: promoter 72.74%31 Mar 2025: promoter 72.74%30 Jun 2025: promoter 72.74%30 Sept 2025: promoter 72.74%31 Dec 2025: promoter 72.74%31 Mar 2026: promoter 72.74%30 Jun 2026: promoter 72.49%
2022-052026-06
  • Promoter
  • Public and others
Promoter
72.49%
Public
27.51%
Promoter change
-0.25 pp
Filed
21 Jul 2026
FII
0.05%
DII
0.02%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations80.288.099.890.893.589.195.0104.2120.3127.5149.2139.2
Other income3.23.73.75.95.1(0.1)(1.0)6.42.14.62.57.4
Total income83.491.6103.496.698.689.094.0110.5122.3132.1151.7146.6
Total expenses69.577.387.384.985.387.792.998.7109.3111.5133.9122.1
└ Finance costs0.40.30.50.40.30.61.01.21.21.11.01.0
└ Depreciation2.92.92.93.03.03.13.34.35.15.25.15.3
Profit before tax13.914.316.111.813.31.31.111.813.020.717.824.5
Tax expense3.54.33.82.63.5(0.0)0.52.63.35.04.36.1
Net profit10.510.012.39.29.81.30.59.29.615.713.518.4
EPS16.9616.2419.9514.9215.882.070.8814.9615.5825.4021.8329.78
Net margin13.07%11.41%12.35%10.16%10.50%1.43%0.57%8.87%8.00%12.31%9.04%13.22%
PBT margin17.38%16.29%16.13%12.99%14.26%1.42%1.12%11.36%10.78%16.21%11.94%17.59%
Tax rate24.81%29.98%23.42%21.79%26.38%-0.89%48.72%21.95%25.74%24.09%24.29%24.84%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 12 Aug 2026.

NGLFINE at a glance

  • NGLFINE closed at ₹3,122.1 on 6 Oct 2026, +4.48% on the day, +124.9% over one year, 13.3% below its 52-week high of ₹3,602.
  • Delivery was 28.7% of traded quantity on 6 Oct 2026, the 2nd percentile of its own 1,050 sessions with a reading (20-session average 47.3%, 1-year average 56.9%).
  • Market capitalisation is ₹1,929 crore at a trailing P/E of 33.7 (trailing EPS ₹92.58).
  • Q1 FY27 results (consolidated, filed 12 Aug 2026): revenue ₹139 crore (+33.6% year on year), net profit ₹18 crore (+99.1%); the price moved +0.8% on the first session after.
  • Promoters held 72.49% at 30 Jun 2026, down 0.25 percentage points on the previous filing.
  • Q2 FY27 results are expected between 29 Oct 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE887E01022
SeriesEQ
Listed8 Jul 2022
History from8 Jul 2022
Sessions1,052

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE